Walleye Capital LLC Sells 986,453 Shares of Autolus Therapeutics plc (NASDAQ:AUTL)

Walleye Capital LLC decreased its holdings in shares of Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 92.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 75,940 shares of the company's stock after selling 986,453 shares during the quarter. Walleye Capital LLC's holdings in Autolus Therapeutics were worth $178,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of AUTL. Barclays PLC grew its stake in Autolus Therapeutics by 1,094.3% in the 4th quarter. Barclays PLC now owns 11,859 shares of the company's stock valued at $28,000 after buying an additional 10,866 shares during the last quarter. Dumont & Blake Investment Advisors LLC acquired a new stake in shares of Autolus Therapeutics in the fourth quarter valued at about $35,000. Arkadios Wealth Advisors bought a new position in shares of Autolus Therapeutics in the fourth quarter worth about $47,000. Daiwa Securities Group Inc. lifted its position in shares of Autolus Therapeutics by 55.5% during the 4th quarter. Daiwa Securities Group Inc. now owns 23,743 shares of the company's stock worth $56,000 after purchasing an additional 8,479 shares during the last quarter. Finally, Avanza Fonder AB bought a new stake in Autolus Therapeutics during the 4th quarter valued at approximately $75,000. Institutional investors own 72.83% of the company's stock.

Autolus Therapeutics Stock Performance

Shares of AUTL stock traded up $0.05 during mid-day trading on Friday, reaching $1.40. The company's stock had a trading volume of 416,790 shares, compared to its average volume of 1,418,974. The firm's 50-day moving average is $1.59 and its two-hundred day moving average is $2.39. The company has a market cap of $372.53 million, a P/E ratio of -1.16 and a beta of 2.06. Autolus Therapeutics plc has a 1-year low of $1.11 and a 1-year high of $5.00.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last announced its quarterly earnings results on Thursday, March 20th. The company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.21) by $0.12. The business had revenue of $0.03 million for the quarter, compared to the consensus estimate of $2.98 million. Sell-side analysts anticipate that Autolus Therapeutics plc will post -0.94 EPS for the current year.

Wall Street Analysts Forecast Growth

AUTL has been the topic of a number of research reports. Needham & Company LLC reaffirmed a "buy" rating and set a $10.00 target price on shares of Autolus Therapeutics in a research report on Thursday, April 10th. Wells Fargo & Company cut their price objective on shares of Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating for the company in a research report on Friday, March 21st. Finally, Truist Financial reduced their target price on shares of Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $9.32.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.